


JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



CATHY BETTS
DIRECTOR
KA LUNA HO'OKELE

JOSEPH CAMPOS II
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

STATE OF HAWAII
KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF HUMAN SERVICES
KA 'OIHANA MĀLAMA LAWELAWE KANAKA
Med-QUEST Division
Clinical Standards Office
P. O. Box 700190
Kapolei, Hawaii 96709-0190

TRISTA SPEER
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

Minutes of Remote Meeting
Med-QUEST Drug Use Review (DUR) Board Meeting

Date: November 10, 2021

Time: 12:05 pm

Department of Human Services TEAMS Conference Call

Members Present:

Dr. James Lumeng, Chair
Angela Yogi, Vice-Chair, Pharmacist
Wendell Au, Pharmacist
Eddie Fox, Medical Service Representative
Miki Lei Morita, Pharmacist
Reed Muraoka, Pharmacist
Dr. Greg Yuen

Members Absent:

None

Staff present:

Dr. Dan Fujii, Clinical Standards Office, Dental Consultant
Kathleen T. Kang-Kaulupali, Clinical Standards Office DUR Coordinator, Pharmacist
Leslie Tawata, Clinical Standards Office, Administrator
Dr. Curtis Toma, Clinical Standards Office, Medical Director

Guests:

Dr. Lynette Honbo, Koan Risk Solutions
Gary Peton, Conduent Government Healthcare (Medicaid fiscal agent), pharmacist

- I. Chair Dr. James Lumeng called the meeting to order at 12:05 pm.
- II. Quorum of 7 members was present, as reported by the DUR Coordinator. Other support members of the Drug Use Review Board were noted: Lynette Honbo, Koan Risk Solutions, Medical Doctor (present) and Gary Peton, Conduent Government Healthcare, Pharmacist (present).
- III. The meeting minutes for September 8, 2021 were reviewed, moved to approve as presented, and were approved unanimously with no abstentions.
- IV. State of Hawaii Organ and Tissue Transplant (SHOTT) Program – presented by Gary Peton, Dr. Lynette Honbo, and Kathleen T. Kang-Kaulupali.
 - Review of claims reimbursing at \$500 or greater
 - Previous post payment review of Ravicti claims and recovery of incorrect payment will be completed by month's end. No further action is required.
 - Stem cell transplant patients with Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) are receiving on-going new expensive neoplastics. Dr. Honbo shared examples of current cases. The Board members discussed national issues around FDA approved studies, experimental trials, high cost newly approved therapies.
 - Dr. Honbo presented the procedures Koan uses to review expensive claims before payment is approved: high cost, patient safety evaluation, and medical necessity.
 - There is no issue with Fee-For-Service (FFS). To improve provider access, it was recommended that links to the managed care health plans updated formularies (by therapeutic categories) be in one place instead of current outdated formulary on the Med-QUEST Division (MQD) website.
 - No motion was made.
- V. Medication Assisted Therapy (MAT) for Opioid Use Disorder (OUD) - presented by Gary Peton
 - The October 1, 2020, deadline for drug rebate reporting of MAT for OUD was accomplished by the managed care health plans and FFS as per federal guidance.
 - 2Q2021: no FFS claims, most claims were reported by HMSA
 - 3Q2021: no FFS claims, HMSA like 2Q2021
 - Data may include 4Q2020 and 1Q2021 retrospective entries as implementation differed by the individual managed care health plans and may require 3-4 quarters to achieve timely capture of data.

- Naloxone/Narcan claim counts for 3Q2020 to 2Q2021 are 117, 117, 118, 113 respectively.
- No motion was made.

VI. Prescription Drug Monitoring Program (PDMP) – presented by Kathleen T. Kang-Kaulupali

- MQD is working on access to the State of Hawaii PDMP as per CMS reporting requirement.
- No motion was made.

VII. Annual review of retrospective DUR from SFY 2021 (7/1/2020 - 6/30/2021) – presented by Gary Peton

- Hepatitis C:
 - No claims were paid by FFS.
 - QUEST Integrated health plans data analysis by drug rebate found costs have decreased and a stable prescription count, especially for Mavyret, which had the highest use.
 - Epcalsa and Harvoni now have generics and not included in this report. The next meeting use will be reported.
- Dental scheduled drugs:
 - The highest prescriber is not actually an outlier, is cutting down on prescribed quantities, writing less oxycodone 10mg and mindful of the 3-day supply (before PDMP reporting is required).
 - Watch dental use of hydrocodone and morphine milligram equivalents (MME) was recommended.
 - A different dentist is performing oral surgeries for the Big Island.
 - One (1) diazepam claim without concurrent pain treatment.
 - Only two (2) managed care health plans referring dental prescriptions to FFS.
- SUPPORT Act Section 1004 retrospective reviews for FFS (Opioids)
 - Fifty-seven (57) patients with opioid claims, all within 120 MME, no PDMP access yet and only one (1) naloxone/Narcan claim.
 - No concurrent opioid and benzodiazepine use.
 - No concurrent opioid and antipsychotic uses.
 - No antipsychotics use in children outside of a long-term care facilities or other institutional settings whose prescriptions are dispensed through a single pharmacy.
 - Annual provider education on opioids was recommended.
- No motion was made.

VIII. The DUR Board meetings for 2022 will continue via video/teleconferencing due to COVID and until the conference room at the Liliuokalani Building is no longer closed due to COVID.

- IX. The meeting was adjourned at 1:08 pm by Dr. James Lumeng, Chair, approved unanimously with no abstentions.